Dataset Information

The interpretation of non-hyperbolic rate curves for two-substrate enzymes. A possible mechanism for phosphofructokinase.

ABSTRACT: 1. A theoretical appraisal of the alternative pathway mechanism for a two-substrate enzyme shows that this mechanism is capable of giving rise to apparent substrate inhibition or substrate activation (Dalziel, 1958). It has now been shown that these phenomena may occur simultaneously in the following ways. With certain relationships between the kinetic parameters and the constant concentration of one substrate, A, the plot of initial rate, v, against the concentration of the other substrate, B, may show substrate ;activation' at low concentrations of B and substrate ;inhibition' at high concentrations of B. In other circumstances the plot of v against [B], with [A] constant, may be sigmoid (substrate activation), whereas the plot of v against [A], with [B] constant, may pass through a maximum (substrate inhibition). 2. Kinetic data for phosphofructokinase are of the latter type and it is suggested that the mechanism of this enzyme may involve a kinetically preferred pathway. It is emphasized that the phenomena of substrate inhibition and activation need not necessarily involve more than one binding site for each substrate on the enzyme molecule, nor more than one monomer per molecule.

SUBMITTER: Ferdinand W

PROVIDER: S-EPMC1264826 | biostudies-other | 1966 Jan

REPOSITORIES: biostudies-other

ACCESS DATA

Similar Datasets

Project description:Background: Coronary artery disease distribution along the vessel is a main determinant of FFR improvement after PCI. Identifying focal from diffuse disease from visual inspections of coronary angiogram (CA) and FFR pullback (FFR-PB) are operator-dependent. Computer science may standardize interpretations of such curves. Methods: A virtual stenting algorithm (VSA) was developed to perform an automated FFR-PB curve analysis. A survey analysis of the evaluations of 39 vessels with intermediate disease on CA and a distal FFR <0.8, rated by 5 interventional cardiologists, was performed. Vessel disease distribution and PCI strategy were successively rated based on CA and distal FFR (CA); CA and FFR-PB curve (CA/FFR-PB); and CA and VSA (CA/VSA). Inter-rater reliability was assessed using Fleiss kappa and an agreement analysis of CA/VSA rating with both algorithmic and human evaluation (operator) was performed. We hypothesize that VSA would increase rater agreement in interpretation of epicardial disease distribution and subsequent evaluation of PCI eligibility. Results: Inter-rater reliability in vessel disease assessment by CA, CA/FFR-PB, and CA/VSA were respectively, 0.32 (95% CI: 0.17-0.47), 0.38 (95% CI: 0.23-0.53), and 0.4 (95% CI: 0.25-0.55). The raters' overall agreement in vessel disease distribution and PCI eligibility was higher with the VSA than with the operator (respectively, 67 vs. 42%, and 80 vs. 70%, both p < 0.05). Compared to CA/FFR-PB, CA/VSA induced more reclassification toward a focal disease (92 vs. 56.2%, p < 0.01) with a trend toward more reclassification as eligible for PCI (70.6 vs. 33%, p = 0.06). Change in PCI strategy did not differ between CA/FFR-PB and CA/VSA (23.6 vs. 28.5%, p = 0.38). Conclusions: VSA is a new program to facilitate and standardize the FFR pullback curves analysis. When expert reviewers integrate VSA data, their assessments are less variable which might help to standardize PCI eligibility and strategy evaluations. Clinical Trial Registration: https://www.clinicaltrials.gov/ct2/show/NCT03824600.

Dataset Information

The interpretation of non-hyperbolic rate curves for two-substrate enzymes. A possible mechanism for phosphofructokinase.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets